Last mentioned: Mar 26, 2026
Litigation Wave
Expected increase in consumer protection lawsuits regarding cannabis health claims.
State Regulatory Review
State health departments begin formal reviews of medical marijuana qualifying conditions.
National Media Coverage
CNN and 6abc report on the findings, sparking industry-wide debate.
Scientific Report Published
Comprehensive study on cannabis and mental health efficacy released to the public.
Impurity Warning
Lilly issues formal warning after testing reveals impurities in compounded samples.
Compounding Surge
Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.
Zepbound Approval
Tirzepatide approved for chronic weight management, exacerbating supply shortages.
Mounjaro FDA Approval
FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.
New scientific findings indicate that marijuana does not effectively treat anxiety or other mental health conditions, creating a significant regulatory and legal crisis for the medical cannabis industry. This development is expected to trigger a wave of consumer protection litigation and force state regulators to re-evaluate qualifying conditions for medical programs.
Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.
The debate over Direct-to-Consumer (DTC) pharmaceutical advertising is intensifying as U.S. regulators face mounting pressure to align with global standards. With the U.S. remaining one of only two nations allowing the practice, new legal and ethical challenges are questioning the impact of multi-billion dollar marketing budgets on drug pricing and patient safety.
This page surfaces every story mentioning FDA across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |